Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study highlights the recent FDA approval of baricitinib as the first on-label treatment for severe alopecia areata, whereas previous treatments were off-label therapies like systemic steroids and immunosuppressants.

In this study, researchers used a mouse model of alopecia areata to demonstrate that both ruxolitinib and baricitinib, oral JAK inhibitors, reduced hair loss, CD8+ cell infiltration, and expression of disease-related markers, with baricitinib showing greater effectiveness.

In this study, researchers found that disrupting EGFR signaling in mice led to increased inflammation and hair follicle damage but that inhibiting the JAK-STAT1 pathway could restore hair growth and skin function.

In this study, researchers explored the use of a 2-deoxy-D-ribose sodium alginate hydrogel on mice with androgenic alopecia and found it resulted in similar hair regrowth to minoxidil, highlighting increased hair follicle density and angiogenesis.

This study found that CTIP2 is highly expressed in mouse skin during embryogenesis and adulthood, suggesting it may play a role in skin development and homeostasis.

Transplanted human Olig2+ astroglia may help improve learning and memory after a stroke.

In this study, dose-response modeling predicted that once-daily abrocitinib doses of 100 mg and 200 mg may provide a clinically meaningful response in treating moderate-to-severe atopic dermatitis compared to placebo.

This study developed a method using ultra-high performance liquid chromatography-mass spectrometry (UHPLC-MRM-IDA-EPI) for the rapid and sensitive detection of 13 JAK inhibitors in anti-alopecia cosmetics, showing excellent separation and accurate quantification with high recovery rates in tested matrices.

This study found that in immunodeficient mice lacking T cells, certain innate lymphoid cell subsets increased and influenced the hair growth cycle, with specific ILC subsets shown to promote anagen, the active phase of hair growth.

This review summarized the latest knowledge suggesting that Janus kinase inhibitors may have therapeutic potential for treating skin diseases like atopic dermatitis and psoriasis, especially when conventional therapies do not work.

This study found that JAK inhibitor treatment in patients with alopecia areata was associated with a lower incidence of major depressive disorder and decreased antidepressant usage.

This study found that HtrA2 inactivation in mnd2 mice is associated with delayed hair cycle phases and growth retardation of adipocytes, suggesting HtrA2's role in regulating adipogenesis-related hair growth.

This study found that the IGF2 gene Apa1 A820G polymorphism is associated with an increased risk of developing PCOS in the studied population.

In this study, l-Ascorbic acid 2-phosphate was found to stimulate hair follicle growth in vitro by promoting IGF-1 expression via the PI3K pathway.

This research letter discusses the use of Janus kinase inhibitors for treating lichen planopilaris, although specific results or conclusions from the study are not provided.

This article discusses Janus kinase inhibitors as a promising future treatment for alopecia areata but does not present new research findings.

This study suggests that Orostachys iwarenge extract may promote hair growth by increasing the proliferation of dermal papilla cells in an in-vitro setting.

This study identified natural compounds from Iris plants that showed potential as inhibitors of urease and carbonic anhydrase-II enzymes, suggesting their possible use in treating related disorders.

In this study, scalp biopsies from HJMD patients revealed histological similarities to chronic telogen effluvium and highlighted the role of CDH3 mutations disrupting normal hair cycles.

This description of dystrophy hypotrichosis associated with juvenile macular dystrophy provides an overview of this rare disorder characterized by short hair from birth and progressive loss of central vision but reports no new findings.

Baricitinib stops hair loss and promotes regrowth in alopecia areata.

In this study, JAK inhibitors for treating alopecia areata and atopic dermatitis were generally well tolerated in a real-world setting, with most adverse events being mild or moderate and rare serious cases resembling the general population incidence.

This case report identifies a novel CDH3 gene mutation associated with hypotrichosis with juvenile macular dystrophy in a 13-year-old Turkish girl, highlighting implications for future genetic analysis and counseling.

This study documented a case where the medication baricitinib effectively promoted hair regrowth in a woman with alopecia areata but also led to an unexpected side effect of hypertrichosis, suggesting a need to further explore the JAK/STAT pathway's role in hair growth dynamics.

This study demonstrated that in live rodents, actin filaments adjust their structure to facilitate membrane transfer between cellular compartments with different biophysical properties.

Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.